Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 5,272 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Completed Phase 3 Interventional

Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial

NCT00731627
View directory record Official record
Conditions
Subarachnoid Haemorrhage
Interventions
placebo, simvastatin
Drug
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Other
Eligibility
18 Years to 65 Years
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 23, 2026, 5:26 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NCT03126916
View directory record Official record
Conditions
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 30 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
152
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.

NCT03218787
View directory record Official record
Conditions
Coronary Artery Lesions
Interventions
XIENCE, DAPT
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
101
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)

NCT01418352
View directory record Official record
Conditions
Tourette's Disorder
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
7 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Dothan, Alabama • San Francisco, California • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 23, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

NCT02523014
View directory record Official record
Conditions
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Interventions
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
784
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 511 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT04577404
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
MT-1186
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Rogers, Arkansas • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 1 Interventional

PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

NCT04837547
View directory record Official record
Conditions
Neuroblastoma, Diffuse Intrinsic Pontine Glioma
Interventions
Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
Biological
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
3
States / cities
Gainesville, Florida • Charlotte, North Carolina • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Not applicable Interventional

Study of Artelon FLEXBAND® for Patients Undergoing Soft Tissue Reconstruction of the Anterior Talofibular Ligament (ATFL) to Treat Lateral Ankle Instability

NCT06638138
View directory record Official record
Conditions
Lateral Ankle Instability
Interventions
Flexband
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 4

NCT05617014
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

NCT07795814
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
EDG-15400 25 mg, Placebo to match EDG-15400 25 mg or 50 mg, EDG-15400 50 mg
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
30 Years to 84 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma

NCT00311584
View directory record Official record
Conditions
Neuroblastoma
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 96 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation

NCT02444052
View directory record Official record
Conditions
Alveolar Bone Grafting, Allograft, Dental Extraction, Dental Implant, Socket Preservation
Interventions
Zimmer Puros Cancellous Allograft, Nobel Biocare Creos Cancellous Allograft
Device
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting Phase 3 Interventional

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

NCT05908084
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Acellular Tissue Engineered Vessel (ATEV), AVF
Biological · Other
Lead sponsor
Humacyte, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
32
States / cities
Scottsdale, Arizona • El Centro, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial

NCT03429413
View directory record Official record
Conditions
Human Papillomavirus (HPV) Vaccines
Interventions
Protect Me 4 Application + External Quality Improvement Support, Protect Me 4 Application Alone
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
1,296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

NCT00288080
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dexamethasone, Prednisone, docetaxel, Oral antiandrogen, Radiation therapy, LHRH agonist
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
245
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 194 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 23, 2026, 5:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

NCT06121297
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis
Interventions
CABA-201
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
12 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
21
States / cities
Orange, California • Sacramento, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Not applicable Interventional Results available

The Angel® Catheter Pivotal Clinical Trial

NCT02186223
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
Interventions
The Angel® Catheter
Device
Lead sponsor
BiO2 Medical
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
21
States / cities
Los Angeles, California • San Diego, California • Loveland, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

NCT00193596
View directory record Official record
Conditions
Neoplasms, Unknown Primary
Interventions
Etoposide, Gemcitabine, Irinotecan, Paclitaxel, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
31
States / cities
Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 28 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

NCT03691662
View directory record Official record
Conditions
Glaucoma and Ocular Hypertension
Interventions
DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
12 Months and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
34
States / cities
Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2023 · Synced Oct 23, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Assessment in Newborns for Diabetes Autoimmunity

NCT00649246
View directory record Official record
Conditions
Type 1 Diabetes, Autoimmunity
Interventions
Not listed
Lead sponsor
Augusta University
Other
Eligibility
Not listed
Enrollment
25,055 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2010
U.S. locations
3
States / cities
Gainesville, Florida • Charleston, South Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01303796
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Sapacitabine, Decitabine
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
70 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

NCT01242488
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc, Placebo iv
Biological · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
74
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 23, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

NCT00731211
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pazopanib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
17
States / cities
San Francisco, California • Fort Myers, Florida • Lakeland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 23, 2026, 5:26 PM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

NCT05911763
View directory record Official record
Conditions
Hemophilia A
Interventions
Efanesoctocog Alfa BIVV001
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Gilbert, Arizona • Loma Linda, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 5:26 PM EDT